vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and RENASANT CORP (RNST). Click either name above to swap in a different company.

RENASANT CORP is the larger business by last-quarter revenue ($273.8M vs $196.0M, roughly 1.4× Axsome Therapeutics, Inc.). RENASANT CORP runs the higher net margin — 32.2% vs -14.6%, a 46.8% gap on every dollar of revenue. Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 29.3%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Renasant Bank is an American regional commercial financial institution based in Tupelo, Mississippi. The bank has more than 280 branches in Alabama, Florida, Georgia, Mississippi, Louisiana, Tennessee, North Carolina and South Carolina. Renasant Bank operates under the parent company Renasant Corporation and is affiliated with Renasant Nation, a platform through which they publish blogs and shows.

AXSM vs RNST — Head-to-Head

Bigger by revenue
RNST
RNST
1.4× larger
RNST
$273.8M
$196.0M
AXSM
Higher net margin
RNST
RNST
46.8% more per $
RNST
32.2%
-14.6%
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
29.3%
RNST

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AXSM
AXSM
RNST
RNST
Revenue
$196.0M
$273.8M
Net Profit
$-28.6M
$88.2M
Gross Margin
Operating Margin
-13.8%
Net Margin
-14.6%
32.2%
Revenue YoY
65.0%
Net Profit YoY
61.9%
112.5%
EPS (diluted)
$-0.55
$0.94

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
RNST
RNST
Q1 26
$273.8M
Q4 25
$196.0M
$278.4M
Q3 25
$171.0M
$269.5M
Q2 25
$150.0M
$267.2M
Q1 25
$121.5M
$170.7M
Q4 24
$118.8M
$167.1M
Q3 24
$104.8M
$220.3M
Q2 24
$87.2M
$163.8M
Net Profit
AXSM
AXSM
RNST
RNST
Q1 26
$88.2M
Q4 25
$-28.6M
$78.9M
Q3 25
$-47.2M
$59.8M
Q2 25
$-48.0M
$1.0M
Q1 25
$-59.4M
$41.5M
Q4 24
$-74.9M
$44.7M
Q3 24
$-64.6M
$72.5M
Q2 24
$-79.3M
$38.8M
Operating Margin
AXSM
AXSM
RNST
RNST
Q1 26
Q4 25
-13.8%
34.8%
Q3 25
-27.0%
27.9%
Q2 25
-24.5%
1.0%
Q1 25
-46.9%
30.4%
Q4 24
-61.1%
29.8%
Q3 24
-59.8%
44.2%
Q2 24
-89.5%
29.6%
Net Margin
AXSM
AXSM
RNST
RNST
Q1 26
32.2%
Q4 25
-14.6%
28.4%
Q3 25
-27.6%
22.2%
Q2 25
-32.0%
0.4%
Q1 25
-48.9%
24.3%
Q4 24
-63.1%
26.8%
Q3 24
-61.7%
32.9%
Q2 24
-91.0%
23.7%
EPS (diluted)
AXSM
AXSM
RNST
RNST
Q1 26
$0.94
Q4 25
$-0.55
$0.78
Q3 25
$-0.94
$0.63
Q2 25
$-0.97
$0.01
Q1 25
$-1.22
$0.65
Q4 24
$-1.54
$0.70
Q3 24
$-1.34
$1.18
Q2 24
$-1.67
$0.69

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
RNST
RNST
Cash + ST InvestmentsLiquidity on hand
$322.9M
$1.2B
Total DebtLower is stronger
$806.2M
Stockholders' EquityBook value
$88.3M
$3.9B
Total Assets
$689.8M
$27.1B
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
RNST
RNST
Q1 26
$1.2B
Q4 25
$322.9M
$1.1B
Q3 25
$325.3M
$1.1B
Q2 25
$303.0M
$1.4B
Q1 25
$300.9M
$1.1B
Q4 24
$315.4M
$1.1B
Q3 24
$327.3M
$1.3B
Q2 24
$315.7M
$851.9M
Total Debt
AXSM
AXSM
RNST
RNST
Q1 26
$806.2M
Q4 25
$499.8M
Q3 25
$558.9M
Q2 25
$557.0M
Q1 25
$433.3M
Q4 24
$430.6M
Q3 24
$433.2M
Q2 24
$428.7M
Stockholders' Equity
AXSM
AXSM
RNST
RNST
Q1 26
$3.9B
Q4 25
$88.3M
$3.9B
Q3 25
$73.7M
$3.8B
Q2 25
$73.1M
$3.8B
Q1 25
$53.2M
$2.7B
Q4 24
$57.0M
$2.7B
Q3 24
$92.9M
$2.7B
Q2 24
$102.9M
$2.4B
Total Assets
AXSM
AXSM
RNST
RNST
Q1 26
$27.1B
Q4 25
$689.8M
$26.8B
Q3 25
$669.3M
$26.7B
Q2 25
$639.8M
$26.6B
Q1 25
$596.7M
$18.3B
Q4 24
$568.5M
$18.0B
Q3 24
$561.5M
$18.0B
Q2 24
$548.2M
$17.5B
Debt / Equity
AXSM
AXSM
RNST
RNST
Q1 26
0.21×
Q4 25
0.13×
Q3 25
0.15×
Q2 25
0.15×
Q1 25
0.16×
Q4 24
0.16×
Q3 24
0.16×
Q2 24
0.18×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
RNST
RNST
Operating Cash FlowLast quarter
$-18.7M
Free Cash FlowOCF − Capex
$-18.7M
FCF MarginFCF / Revenue
-9.6%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
RNST
RNST
Q1 26
Q4 25
$-18.7M
$271.5M
Q3 25
$1.0M
$135.5M
Q2 25
$-32.4M
$-77.3M
Q1 25
$-43.4M
$106.2M
Q4 24
$-26.2M
$106.4M
Q3 24
$-18.6M
$-1.7M
Q2 24
$-30.1M
$-49.1M
Free Cash Flow
AXSM
AXSM
RNST
RNST
Q1 26
Q4 25
$-18.7M
$237.8M
Q3 25
$988.0K
$120.1M
Q2 25
$-32.4M
$-87.5M
Q1 25
$-43.7M
$101.3M
Q4 24
$-26.2M
$92.8M
Q3 24
$-18.7M
$-5.3M
Q2 24
$-30.2M
$-52.6M
FCF Margin
AXSM
AXSM
RNST
RNST
Q1 26
Q4 25
-9.6%
85.4%
Q3 25
0.6%
44.6%
Q2 25
-21.6%
-32.7%
Q1 25
-36.0%
59.4%
Q4 24
-22.1%
55.5%
Q3 24
-17.9%
-2.4%
Q2 24
-34.6%
-32.1%
Capex Intensity
AXSM
AXSM
RNST
RNST
Q1 26
Q4 25
0.0%
12.1%
Q3 25
0.0%
5.7%
Q2 25
0.0%
3.8%
Q1 25
0.3%
2.8%
Q4 24
0.0%
8.2%
Q3 24
0.1%
1.6%
Q2 24
0.1%
2.1%
Cash Conversion
AXSM
AXSM
RNST
RNST
Q1 26
Q4 25
3.44×
Q3 25
2.27×
Q2 25
-75.92×
Q1 25
2.56×
Q4 24
2.38×
Q3 24
-0.02×
Q2 24
-1.26×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Segment breakdown not available.

RNST
RNST

Net Interest Income$223.6M82%
Noninterest Income$50.3M18%

Related Comparisons